(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.23%) $78.30
(1.32%) $2.22
(-0.39%) $2 322.00
(-0.42%) $27.50
(2.41%) $988.20
(0.17%) $0.930
(0.77%) $10.91
(0.45%) $0.799
(-0.07%) $91.28
0.00% $ 0.203
Live Chart Being Loaded With Signals
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform...
Stats | |
---|---|
Dzisiejszy wolumen | 1.75M |
Średni wolumen | 263 314 |
Kapitalizacja rynkowa | 2.33M |
EPS | $0 ( 2024-03-18 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0194 |
ATR14 | $0.141 (69.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-05 | Lau Johnson Yiu Nam | Buy | 8 382 | Common Stock |
2023-05-05 | Kwan Rudolf | Buy | 3 603 | Common Stock |
2023-05-05 | Cook Timothy Devere | Buy | 368 | Common Stock |
2023-04-21 | Wu Jinn | Buy | 6 513 | Common Stock |
2023-04-21 | Vierling John | Buy | 6 513 | Common Stock |
INSIDER POWER |
---|
94.87 |
Last 100 transactions |
Buy: 1 577 577 | Sell: 76 746 |
Wolumen Korelacja
Athenex Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
RUBY | 0.962 |
PETS | 0.952 |
IMKTA | 0.951 |
MRBK | 0.949 |
SSTI | 0.948 |
VERU | 0.948 |
CYXT | 0.946 |
AGIL | 0.946 |
CUE | 0.945 |
GOVX | 0.944 |
10 Najbardziej negatywne korelacje | |
---|---|
ISRG | -0.954 |
HBIO | -0.95 |
LMRKO | -0.948 |
TYHT | -0.946 |
VRTX | -0.945 |
ICVX | -0.945 |
CREX | -0.943 |
LMRKP | -0.942 |
ALXN | -0.942 |
BRAC | -0.942 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Athenex Inc Korelacja - Waluta/Towar
Athenex Inc Finanse
Annual | 2022 |
Przychody: | $102.82M |
Zysk brutto: | $26.70M (25.97 %) |
EPS: | $-15.13 |
FY | 2022 |
Przychody: | $102.82M |
Zysk brutto: | $26.70M (25.97 %) |
EPS: | $-15.13 |
FY | 2021 |
Przychody: | $120.18M |
Zysk brutto: | $37.78M (31.43 %) |
EPS: | $-1.920 |
FY | 2020 |
Przychody: | $144.39M |
Zysk brutto: | $49.04M (33.96 %) |
EPS: | $-1.720 |
Financial Reports:
No articles found.
Athenex Inc
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej